358 results
Page 2 of 18
6-K
EX-99.2
vfqxrd16kq5
17 May 22
Current report (foreign)
3:20pm
6-K
EX-99.1
hop2uhsrxp2ij9
19 Apr 22
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
11:32am
6-K
EX-99.1
tg6j t0k05
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.2
3uduc4hjys2 jao1
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm
6-K
EX-99.4
j9v32dimrsm
15 Mar 22
Sanofi recognized by S&P as one of the most sustainability-committed companies
3:52pm
6-K
EX-99.2
3nry bd8naap9a4
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm
6-K
EX-99.2
kyjmaamno
23 Sep 21
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
1:54pm
SC TO-T
EX-99
rijmy86lbuy
16 Aug 21
Third party tender offer statement
8:09am
SC TO-T
EX-99
jsr3 t1u4hj9zm
16 Aug 21
Third party tender offer statement
8:09am
6-K
EX-99.2
5pnz5 5x1xz3z8sot3
9 Aug 21
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
2:54pm
F-3ASR
EX-25.1
la469
30 Jul 21
Automatic shelf registration (foreign)
4:52pm
F-3ASR
y1gm75een34ev8fdq
30 Jul 21
Automatic shelf registration (foreign)
4:52pm
6-K
EX-99.1
zdvq9o2
29 Jul 21
Sales growth accelerated - Full-year guidance raised
9:52am
6-K
EX-99.5
75s0az 1d
30 Jun 21
Sanofi launches dedicated vaccines mRNA Center of Excellence
5:17pm
11-K
fds8y
29 Jun 21
Annual report of employee stock purchases
12:30pm
11-K
1xbjw26tmdbgkrg
29 Jun 21
Annual report of employee stock purchases
12:01pm
6-K
EX-99.1
e9q urgwewvf7x3j4
16 Jun 21
Current report (foreign)
12:57pm
6-K
EX-99.1
q0rp184ri
21 May 21
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
4:16pm